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rhythm outcome. Similarly, there was no change in OT or 
LT in response to DCCV, irrespective of whether SR was 
restored. Successful restoration and maintenance of SR fol-
lowing RFCA of AF is associated with improved global 
thrombotic status with enhanced fibrinolysis. Larger stud-
ies are required to confirm these early results and investigate 
whether improved thrombotic status translates into fewer 
thromboembolic events.
Keywords Atrial fibrillation · Thrombosis · Fibrinolysis · 
Ablation · Cardioversion
Introduction
Patients with atrial fibrillation (AF) exhibit a prothrombotic 
state and are at increased risk of thromboembolic events, 
which is reduced but not abolished by oral anticoagulation 
(OAC) [1, 2]. Left atrial thrombus formation in patients 
with AF is thought to be determined by the components of 
Virchow’s triad, namely blood stasis (due to loss of atrial 
contractility and dilatation of the left atrium), endothelial 
injury (through myocyte hypertrophy, sclerosis and fibroe-
lastosis) and a prothrombotic/hypercoagulable state [2, 3]. 
Endogenous fibrinolysis is a natural defense mechanism 
against lasting thrombus formation, such that the occur-
rence of thrombus is determined by the balance between 
procoagulant factors on the one hand, and effectiveness of 
fibrinolysis on the other. Radiofrequency catheter ablation 
(RFCA) can restore and maintain sinus rhythm (SR) long-
term in patients with AF, with far superior efficacy com-
pared to DCCV. Given that blood stasis due to reduced atrial 
contractility is an important component of Virchow’s triad, 
it could be postulated that restoration of atrial contraction 
in AF patients through restoration of SR with RFCA may 
Abstract Patients with atrial fibrillation (AF) are at 
increased risk of thrombotic events despite oral anticoagu-
lation (OAC). Radiofrequency catheter ablation (RFCA) can 
restore and maintain sinus rhythm (SR) in patients with AF. 
To assess whether RFCA improves thrombotic status. 80 
patients (71% male, 64 ± 12y) with recently diagnosed AF, 
on OAC and scheduled to undergo RFCA or DC cardiover-
sion (DCCV) were recruited. Thrombotic status was assessed 
using the point-of-care global thrombosis test (GTT), before, 
and 4–6 weeks after DCCV and 3 months after RFCA. The 
GTT first measures the time taken for occlusive thrombus 
formation (occlusion time, OT), while the second phase of 
the test measures the time taken to spontaneously dissolve 
this clot through endogenous thrombolysis (lysis time, LT). 
3 months after RFCA, there was a significant reduction in 
LT (1994s [1560; 2475] vs. 1477s [1015; 1878]) in those 
who maintained SR, but not in those who reverted to AF. At 
follow-up, LT was longer in those in AF compared to those 
in SR (AF 2966s [2038; 3879] vs. SR 1477s [1015; 1878]). 
RFCA resulted in no change in OT value, irrespective of 
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favourably reduce the prothrombotic state. It is acknowl-
edged that additional factors including systemic inflam-
mation may also contribute to a procoagulant state, which 
is one of the reasons for the current recommendation for 
continued anticoagulant therapy after successful RFCA. 
Superiority of RFCA, compared to a rate-control strategy, 
in improving symptoms and quality of life as well as the 
haemodynamic benefit in patients with heart failure, is well 
documented [4, 5]. However, whether maintenance of SR 
in AF patients can reduce thrombotic risk, is incompletely 
understood. Large studies, most notably the AFFIRM (atrial 
fibrillation follow-up investigation of rhythm management) 
trial, have not shown a mortality or stroke reduction benefit 
with rhythm control (achieved with antiarrhythmic medi-
cations and cardioversion) compared to rate control [6]. 
However, many more patients in the rhythm control arm 
had discontinued anticoagulation and a post-hoc analysis 
indicated a trend for mortality benefit following restoration 
of SR [7]. Non-randomized data indicate normalization of 
stroke risk following successful AF ablation, suggesting that 
treating the substrate of AF may favourably improve throm-
botic profile [8]. The prothrombotic/hypercoagulable state 
in AF comprises enhanced platelet activation, evidenced by 
raised levels of soluble P-selectin, β-thromboglobulin and 
platelet factor four released from platelet alpha granules; 
as well as raised levels of von Willebrand factor released 
by the endothelium, which mediate subendothelial platelet 
adhesion; enhanced coagulation, through increased levels of 
prothrombin fragments 1 and 2 and thrombin-antithrombin 
III complex; and impaired fibrinolysis [3, 9]. The fibrinolytic 
system plays an important role in regulating local thrombus 
formation. Increased level of tissue-type plasminogen activa-
tor antigen and tissue-type plasminogen activator inhibitor-1 
has been documented in AF [9] which is reduced signifi-
cantly with anticoagulation [9]. D-dimer levels, reflecting 
fibrin turnover, are elevated in patients with AF, especially 
those with left atrial appendage thrombi and are reduced by 
anticoagulation [10]. We aimed to assess whether restoration 
of SR in patients with AF may have favourable effects on 
thrombotic profile, and whether modification of the substrate 
of AF, through ablation improves thrombotic status more 
than simple restoration of SR through cardioversion. We 
used a method to assess thrombotic status that would capture 
changes in platelet activation, coagulation, and fibrinolysis, 
which are felt to belie the prothrombotic/hypercoagulable 
state in AF. To further assess whether changes in thrombotic 
status were systemic or local to the left atrium, we compared 
blood from the right and left atria with peripheral blood, in 
patients with and without AF undergoing ablation.
Methods
Patients, clinical procedures and follow‑up
The study was approved by the National Research Ethics 
Service. 80 patients with AF scheduled to undergo direct 
current cardioversion (DCCV) (n = 40) or RFCA (n = 40) 
were enrolled after obtaining written informed consent. The 
exclusion criteria in Table 1 were applied. Venous blood was 
taken at 2 time-points from each patient; at baseline and at 
post-procedural follow up. Patients acted as self-controls.
Baseline demographics and clinical characteristics were 
obtained from patients, review of case notes and electronic 
patient records, at baseline and at follow-up, which was 
approximately 4–6 weeks after DCCV and 3 months after 
RFCA. The end-study visit involved assessment of throm-
botic status, review of the 24-h Holter monitor and ECG 
results, and verification of other clinical characteristics.
Patients had been therapeutically anticoagulated for at 
least 4 weeks pre-DCCV. Non-vitamin K oral anticoagulants 
(NOAC) were taken on the day of the procedure. Cardio-
version was performed according to standard local protocol 
under general anesthesia, delivering up to three biphasic 
synchronized shocks. 29 patients were successfully cardio-
verted to SR. Digoxin was stopped if SR was restored, but 
Table 1  Exclusion criteria
eGFR estimated glomerular filtration rate, Hb haemoglobin, UNL upper normal limit
Exclusion criteria
Age  <18 years
Impaired renal function with eGFR < 30 mL/min (since renal failure is associated with platelet function defect that may confound results)
Persons who, in the opinion of the investigator, have significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmo-
nary, haemorrhagic, metabolic or other disease likely to confound the study results
Persons with a history of substance abuse or who demonstrates signs or clinical features of active substance abuse or psychiatric disease
Alcohol consumption above recommended safe levels (i.e. above 21 units per week for males, or 14 units per week for females) due to the poten-
tial effects of high alcohol levels on platelet reactivity
Any illness deemed significant by the investigator during the 4 weeks preceding the screening period of the study
Blood dyscrasia (platelets <70 × 109/l, Hb <80 g/dl, leucocyte count <3.5 × 109/l, neutrophil count <1 × 109/l), or known bleeding disorder
Subject currently enrolled in an investigational device or drug trial
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other medications were continued. At 6 weeks’ follow-up, 
9 patients had AF recurrence, as evidenced by 24-h Holter 
monitoring and ECG. In patients taking warfarin, INR levels 
were similar before DCCV and at follow-up (2.5 ± 0.33 vs. 
2.4 ± 0.40; p = 0.24).
Patients undergoing RFCA had been therapeutically 
anticoagulated for at least 4 weeks. The morning dose of 
dabigatran was taken the morning of the day before the pro-
cedure. RFCA was performed according to standard local 
protocol under general anesthesia. All procedures were 
performed with a 3D mapping system, either CARTO3 
(Biosense, Diamond Bar, CA, USA) or Velocity (St Jude 
Medical), alongside conventional mapping systems and irri-
gated ablation catheters. Wide area circumferential ablation 
with pulmonary vein isolation was performed in all patients, 
accompanied by linear ablation in the left and/or right atria 
with validation of line integrity, and limited electrogram-
based ablation as clinically indicated. There were no major 
peri-procedural complications. No changes to medications 
were made post-procedure. At 3 months, AF recurred in 10 
out of 40 RFCA patients. INR levels at baseline and follow-
up were similar (2.37 ± 0.44 vs. 2.33 ± 0.40; p = 0.67).
Blood sampling
Peripheral blood samples were taken on 2 occasions: (1) just 
before DCCV or RFCA, and (2) at follow-up, approximately 
4–6 weeks after DCCV and 3 months after RFCA. Blood 
was obtained from an ante-cubital vein using an 18-G but-
terfly cannula with a two-syringe technique, taking care to 
avoid prolonged tourniquet time. The two-syringe technique 
involved discarding the first 5 mL of blood and using the 
second 5 mL for assessment of thrombotic status.
Assessment of thrombotic status
Assessment of thrombotic status was performed using the 
global thrombosis test (GTT) (Thromboquest Ltd., London, 
UK). This automated point-of-care test sequentially assesses 
both platelet reactivity and endogenous thrombolysis from 
a native blood sample. The patient was positioned in close 
proximity to the GTT such that the blood sample was 
injected into the instrument within 15 s of withdrawal and 
the automated measurement begun. The GTT assesses the 
time taken to form an occlusive platelet thrombus (occlusion 
time, OT), and in the second phase of the test, measures the 
time required to dissolve the thrombus formed in the first 
phase, through endogenous thrombolysis, which restores 
flow (lysis time, LT). The principle of the GTT has previ-
ously been described [11]. In brief, blood flows under physi-
ological conditions through narrow gaps where it is sub-
jected to high shear, and the instrument measures the time 
(d) between two consecutive blood drops downstream of 
this. As shear-induced platelet aggregation causes thrombus 
to form near the gaps, the time interval gradually increases 
as flow slows down and at an arbitrary point (d ≥ 15 s, before 
reaching complete occlusion), the end point of the measure-
ment is displayed. The maximum time allowed for occlusive 
thrombus formation was pre-set to 800 s. Following this, 
there is a preset “thrombus stabilization time” of 200 s, dur-
ing which the sensors are inactive. This time allows stabili-
zation of the formed thrombi to allow lasting occlusion and 
ignores small re-bleeds. Restart of blood flow after occlusion 
is due to spontaneous thrombolysis. If lysis does not occur 
until >6000 s (LT cut-off time), “no lysis” is recorded. The 
coefficient of variation (cv) was assessed by testing a cohort 
of 10 stable patients on two occasions, 48 h apart.
Chamber‑specific assessment of thrombotic status
In order to assess whether the prothrombotic state that 
exists in the left atrium of patients with AF is a local or 
systemic phenomenon, and to assess the chamber-specific 
differences in thrombotic status, in a separate group of 20 
patients undergoing RFCA of AF or left atrial tachycardia 
for conventional clinical indications, thrombotic status was 
assessed in blood taken peripherally and from intra-cardiac 
chambers (Supplementary Table 1) at baseline before abla-
tion. Blood samples were obtained from the femoral vein, 
right atrium and left atrium (prior to heparin administration) 
at the beginning of the procedure. Ablation was performed 
as above, according to standard protocols. Additional sam-
pling was performed after heparin administration and at the 
end of the procedure (after administration of protamine to 
reverse heparin). Further samples were taken 4 h after abla-
tion and at 3 months’ follow-up from a peripheral vein.
Statistical analysis
Since this was a pilot study and patients acted as self-con-
trols with pre- and post- intervention sampling to mini-
mise any bias or confounders, samples of 40 patients per 
group were felt to be sufficient. Data are presented as mean 
and standard deviation for normally distributed or median 
[interquartile range] for skewed continuous variables and as 
proportions for categorical variables. Differences in OT/LT 
before and after DCCV/RFCA within one group were ana-
lyzed by paired t-test or Wilcoxon’s method. Between group 
comparisons for continuous variables were assessed using 
a t-test or Mann–Whitney U test. The Kruskal–Wallis rank 
test was used to compare differences in baseline thrombotic 
status between patients with different types of AF. Dichoto-
mous variables were compared using Chi square test with 
continuity correction or Fisher’s exact test, as appropriate. 
Correlations were performed using Spearman’s rank corre-
lation. Univariate and multivariate linear regression models 
416 M. Niespialowska-Steuden et al.
1 3
Table 2  Baseline characteristics of patients undergoing direct current cardioversion (DCCV) and radiofrequency ablation (RFCA), n (%)
Patient characteristic DCCV cohort (n = 40) RFCA cohort (n = 40) p value
Age, years 63.9 ± 11.6 64 ± 13 0.534
Male 29 (72) 28 (70) 0.851
BMI 28.7 ± 6 28.5 ± 5 0.793
Paroxysmal AF N/A 10 (25) N/A
Persistent AF 19 (48) 9 (23) 0.034
Long-standing persistent AF 21 (53) 21 (53) 1
Medical history
 Hypertension 22 (55) 11 (27.5) 0.023
 Diabetes mellitus 5 (13) 5 (13) 0.996
 Hyperlipidemia 18 (45) 17 (42) 0.851
 Metabolic syndrome 16 (40) 10 (25) 0.188
 Coronary artery disease 4 (10) 8 (20) 0.444
 Prior stroke/TIA 2 (5) 4 (10) 0.703
 Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) 5 (13) 5 (13) 0.996
Echocardiographic characteristics
 Ejection fraction >55% 20 (50) 30 (75) 0.284
 Ejection fraction 45–54% 18 (45) 7 (18) 0.067
 Ejection fraction <44% 2 (5) 3 (8) 0.703
 No atrial dilatation 11 (27) 6 (15) 0.703
 Mild atrial dilatation (LA diameter 4.1–4.6 cm) 18 (45) 25 (63) 0.179
 Moderate atrial dilatation (LA diameter 4.7–5.2 cm) 9 (23) 5 (13) 0.179
 Severe atrial dilatation (LA diameter >5.3 cm) 2 (5) 4 (10) 0.703
Risk scores
 CHA2DS2VASc 1.9 ± 1.39 1.9 ± 1.7 0.798
 HASBLED 1.25 ± 0.83 1.2 ± 0.7 0.754
Medications
 Warfarin 20 (50) 36 (90) 0.116
 Apixaban 2 (5) 0 (0) N/A
 Rivaroxaban 1 (3) 0 (0) N/A
 Dabigatran 17 (42) 4 (10) 0.013
 Beta-blocker 31 (77) 21 (53) 0.179
 Calcium channel blocker 10 (25) 6 (15) 0.444
 Digoxin 6 (15) 1 (2.5) 0.338
 Amiodarone 1 (3) 6 (15) 0.338
 Statin 13 (32) 17 (43) 0.444
 ACE inhibitor 11 (27) 6 (15) 0.338
 ARB 8 (20) 6 (15) 0.703
Laboratory characteristics
 Haemoglobin (g/L) 144.6 ± 15 139 ± 17 0.186
 Haematocrit (%) 0.43 ± 0.04 0.41 ± 4 0.159
 Platelet count (×109/L) 234 ± 83 212 ± 58 0.508
 INR (warfarin patients) 2.32 ± 0.47 2.3 ± 0.4 0.099
 Creatinine (μmol/L) 83.2 ± 14.5 95 ± 84 0.411
 eGFR (mL/min/1.73 m2) 87.6 ± 25 96.6 ± 28 0.145
 Total cholesterol (mmol/L) 5.2 ± 1.2 5.0 ± 1.7 0.428
 CRP (mg/L) 3.8 ± 4.53 3.52 ± 4.18 0.778
 Fibrinogen (g/L) 4.1 ± 1.14 4.06 ± 1.64 0.893
 Baseline OT (s) 488 [396–573] 524 [445–641] 0.123
 Baseline LT (s) 1819 [1453–2180] 2015 [1507–2740] 0.148
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were used to identify the independent predictors of impaired 
fibrinolysis in the DCCV and ablation cohorts. All the study 
variables listed in Tables 2 and 3 were first analysed with 
univariate analysis and those that showed a significant inter-
action (p < 0.05) in the univariate analysis were entered into 
the multivariate analysis. Statistical significance was fixed at 
0.05. Analyses were performed with STATISTICA software 
(StatSoft, version 10).
Results
Clinical characteristics of the DCCV and RFCA cohorts are 
shown in Tables 2, 3 and 4. The cv for OT and LT was 8 and 
10%, respectively. The variables in Tables 2, 3 and 4 were 
interrogated for relation to pre- and post-procedural OT and 
LT in each cohort. In the DCCV cohort, there was a trend 
for an inverse relationship between baseline OT and haemo-
globin level (r = −0.495; p = 0.08) but not to other variables. 
In the RFCA cohort, there was a weak inverse correlation 
between baseline OT and BMI (r = −0.358; p = 0.025). Base-
line LT correlated with creatinine (r = 0.331; p = 0.044). LT 
after RFCA correlated with creatinine (r = 0.504; p = 0.001) 
and weakly with haematocrit (r = 0.35; p = 0.049). Applying 
the Kruskal–Wallis rank test to the group as a whole (DCCV 
and RFA groups combined), we found that baseline OT was 
not different between patients with persistent AF, paroxys-
mal AF, and long-standing persistent AF (497 [402–571] vs. 
640 [505–729] vs. 497 [420–603] respectively; p = 0.100). 
Similarly, baseline LT did not differ between patients 
with different types of AF (1769 [1527–2217] vs. 2128 
[1706–4537] vs. 1852 [1346–2228] respectively; p = 0.275).
Effect of AF ablation on thrombotic status
In the ablation cohort, 10 of the 40 patients had AF recur-
rence at follow-up, which was associated with longer abla-
tion procedure duration (p = 0.001), longer ablation time 
(p = 0.002), and higher energy application (p = 0.005) 
(Table 4).
In the group as a whole, there was no difference in OT 
before and after RFCA (523s [443; 640] vs. 571s [463; 682]; 
p = 0.139), regardless of whether patients were in AF at fol-
low-up (493s [457; 691] vs. 552s [436; 685]; p = 0.514) or in 
SR (527s [440; 640] vs. 571s [476; 679]; p = 0.135) (Figs. 1, 
2). At follow-up, there was no difference in OT between 
patients in SR and those in AF (571 s [476; 679] vs. 552 s 
[436; 685]; p = 0.9).
In the RFCA cohort as a whole, LT was shorter after 
RFCA (2015s [1506; 2739] vs. 1645s [1037; 2285]; 
p = 0.014) (Figs. 1, 2). Among patients in SR at follow-up, 
there was a significant reduction in LT following RFCA 
(1994s [1560; 2475] vs. 1477s [1015; 1878]; p < 0.001), 
whereas there was no change in LT in those in AF at follow-
up (2074s [1453; 3859] vs. 2966s [2038; 3879]; p = 0.500) 
(Figs. 2, 3). At follow-up, LT was significantly longer in 
those in AF compared to those in SR (2966s [2038; 3879] 
vs. 1477s [1015; 1878]; p = 0.002). Pre-ablation samples 
showed no baseline differences in LT between those who 
subsequently reverted to AF and those who maintained SR 
(2074s [1453; 3859] vs. 1994s [1560; 2475]; p = 0.606). 
Amongst patients undergoing RFCA, there was no difference 
between patients pre-and post-RFCA with respect to C-reac-
tive protein (CRP, 3.52 ± 4.18 vs. 2.62 ± 3.01, p = 0.279) or 
fibrinogen (4.06 ± 1.64 vs. 4.39 ± 1.46, p = 0.337). In the 
subgroup who reverted to AF, there was no difference in 
CRP (3.3 ± 3.97 vs. 3.2 ± 3.15, p = 0.955) or fibrinogen 
(4.35 ± 1.32 vs. 4.48 ± 1.55, p = 0.847) before and after the 
procedure. In the subgroup who maintained SR, there was 
no difference in CRP (3.6 ± 4.31 vs. 2.43 ± 2.99; p = 0.223) 
or fibrinogen (3.96 ± 1.74 vs. 4.36 ± 1.46; p = 0.332) before 
and after the procedure.
In the ablation group, using univariate linear regres-
sion analysis, only the following variables were related to 
enhanced fibrinolysis (reduced delta LT): energy applica-
tion (p = 0.039) and sinus rhythm at follow-up (p = 0.009). 
None of the other variables, including all clinical, proce-
dural or haematological parameters listed in Tables 2 and 3, 
correlated with enhanced fibrinolysis. Multivariate analysis 
showed that sinus rhythm at follow-up remained a predictor 
of enhanced fibrinolysis after adjustment for other risk fac-
tors (p = 0.028).
Effect of cardioversion on thrombotic status
In the cardioversion cohort, 20 of the 40 patients had 
reverted to AF at follow-up. In the group as a whole, there 
was no difference in OT before and after DCCV (median 
[interquartile range], 487s [395; 573] vs. 482s [398; 639]; 
p = 0.247), nor in the subgroup who were in AF at follow-up 
Table 2  (continued)
Left ventricular ejection fraction was calculated by Simpson’s method
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CRP C-reactive protein, eGFR estimated glo-
merular rate, INR International Normalized Ratio, LA left atrium, N/A not applicable, TIA transient ischaemic attack
Normal values: haemoglobin 130–180 g/L in men and 115–165 g/L in women; haematocrit 40–52% in men and 36–47% in women; platelet 
count 150–400 × 109/L; INR range 2.0–3.0; creatinine 60–110 μmol/L in men and 45–90 μmol/L in women; eGFR: above 90 mL/min/1.73 m2; 
total cholesterol <5.2 mmol/L; CRP 0–10 mg/L; fibrinogen 2–5 g/L
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Table 3  Baseline clinical characteristics of direct current cardioversion (DCCV) cohort, with respect to rhythm outcome at follow-up
Patient characteristic DCCV cohort (n = 40) AF at follow-up (n = 20) SR at follow-up (n = 20) p value
Age, years 63.9 ± 11.6 62.5 ± 12 65.2 ± 11.5 0.472
Male 29 (72%) 15 (75) 14 (70) 0.731
BMI 28.7 ± 6 29.6 ± 7 27.5 ± 4.3 0.358
Medical history
 Hypertension 22 (55) 12 (60) 10 (50) 0.537
 Diabetes mellitus 5 (13) 1 (5) 4 (20) 0.159
 Hyperlipidemia 18 (45) 7 (35) 11 (55) 0.213
 Metabolic syndrome 16 (40) 7 (35) 9 (45) 0.821
 Coronary artery disease 4 (10) 2 (10) 2 (10) 1
 Prior stroke/TIA 2 (5) 1 (5) 1 (5) 1
 Chronic kidney dis-
ease (eGFR < 60 mL/
min/1.73 m2)
5 (12.5) 1 (5) 4 (20) 0.159
Echocardiographic characteristics
 Left ventricular function
 Ejection fraction >55% 20 (50) 9 (45) 11 (55) 0.539
 Ejection fraction 45–54% 18 (45) 9 (45) 9 (45) 1
 Ejection fraction <44% 2 (5) 2 (10) 0 (0) 0.154
 No atrial dilatation 11 (27) 4 (20) 7 (35) 0.3
 Mild atrial dilatation (LA 
diameter 4.1–4.6 cm)
18 (45) 9 (45) 9 (45) 1
 Moderate atrial dilatation (LA 
diameter 4.7–5.2 cm)
9 (22.5) 6 (30) 3 (15) 0.267
 Severe atrial dilatation (LA 
diameter >5.3 cm)
2 (5) 1 (5) 1 (5) 1
Risk scores
 CHA2DS2VASc 1.9 ± 1.39 1.9 ± 1.2 1.9 ± 1.6 1
 HASBLED 1.25 ± 0.83 1.3 ± 0.8 1.2 ± 0.89 0.711
Medications
 Warfarin 20 (50%) 9 (45) 11 (55) 0.539
 Apixaban 2 (5) 0 (0) 2 (10) N/A
 Rivaroxaban 1 (2.5) 1 (5) 0 N/A
 Dabigatran 17 (42) 11 (55) 6 (30) 0.115
 Beta-blocker 31 (77) 15 (75) 16 (80) 0.713
 Calcium channel blocker 10 (25) 7 (35) 3 (15) 0.151
 Digoxin 6 (15) 4 (20) 2 (10) 0.388
 Amiodarone 1 (2.5) 0 (0) 1 (5) 0.323
 Statin 13 (32) 4 (20) 9 (45) 0.095
 ACE inhibitor 11 (27) 8 (40) 3 (15) 0.08
 ARB 8 (20) 5 (25) 3 (15) 0.692
Laboratory characteristics
 Haemoglobin (g/L) 144.6 ± 15 147 ± 14 141 ± 16.7 0.318
 Haematocrit (%) 0.43 ± 0.04 0.43 ± 0.04 0.42 ± 0.05 0.692
 Platelet count (×109/L) 234 ± 83 251 ± 101 208 ± 35.6 0.192
 INR (warfarin patients) 2.54 ± 0.33 2.59 ± 0.37 2.47 ± 0.28 0.673
 Creatinine (μmol/L) 83.2 ± 14.5 85 ± 9.5 81.2 ± 18 0.382
 eGFR (mL/min/1.73 m2) 87.6 ± 25 85.8 ± 21 89 ± 29 0.661
 Total cholesterol (mmol/L) 5.2 ± 1.2 5.7 ± 1.7 4.8 ± 0.5 0.266
 CRP (mg/L) 3.8 ± 4.53 4.25 ± 4.71 3.35 ± 4.42 0.537
 Fibrinogen (g/L) 4.1 ± 1.14 3.93 ± 1.06 4.28 ± 1.21 0.34
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(468s [392; 606] vs. 488s [414; 613]; p = 0.601), nor in 
those in SR (496s [416; 573] vs. 447s [394; 652]; p = 0.232) 
(Figs. 3, 4 and supplementary Fig. 5). At follow-up, there 
was no difference in OT between those patients who were 
in AF and those in SR (490s [394; 656] vs. 511s [398; 718]; 
p = 0.786).
There was no difference in LT before and after DCCV 
(1819s [1453; 2180] vs. 2026s [1647; 2367]; p = 0.052). 
However, compared to baseline, those who were in AF 
at follow-up demonstrated longer LT after DCCV (1852s 
[1346; 2208] vs. 2156s [1713; 2542]; p = 0.005), whereas 
there was no difference in LT before and after DCCV in 
those in SR at follow-up (1711s [1579; 1951] vs. 1877s 
[1216; 2367]; p = 1.000) (Fig. 4). At follow-up, there was no 
significant difference in LT between patients in AF and those 
in SR (2156s [1713; 2542] vs. 1877s [1216; 2367]; p = 0.14).
There was no difference between patients pre-and post-
DCCV with respect to CRP (3.8 ± 4.53 vs. 4.46 ± 6.19; 
p = 0.467) or fibrinogen (4.1 ± 1.14 vs. 3.67 ± 1.18; 
p = 0.115). In the subgroup who reverted to AF, there was 
no difference in CRP (4.25 ± 4.71 vs. 3.85 ± 3.99; p = 0.776) 
or fibrinogen (3.93 ± 1.06 vs. 3.77 ± 1.38; p = 0.733) before 
and after the procedure; similarly, amongst those who main-
tained SR, there was no difference in either CRP (3.35 ± 4.42 
vs. 5.1 ± 7.95; p = 0.158) or fibrinogen (4.28 ± 1.21 vs. 
3.75 ± 1.08; p = 0.089) before and after the procedure.
In the DCCV group, using univariate linear regres-
sion analysis, only the following variables were related to 
enhanced fibrinolysis (reduced delta LT): high platelet count 
(p = 0.035) and angiotensin-converting enzyme inhibitor 
treatment (p = 0.002). None of the other variables includ-
ing all clinical, procedural or haematological parameters in 
Tables 2 and 3 correlated with enhanced fibrinolysis.
Central and peripheral assessment of thrombotic status
Patient and procedural characteristics are shown in Supple-
mentary Table 1 and thrombotic status in Supplementary 
Table 2. Amongst patients with AF or left sided atrial tachy-
cardia, there was no difference in OT or LT between blood 
samples from the femoral vein, right atrium or left atrium. 
Immediately after ablation, OT was significantly and pro-
foundly prolonged, likely due to the effect of heparin, such 
that occlusive thrombus formation did not occur within the 
cut-off time of the test (800 s) and therefore LT also could 
not be measured (recorded as LT >6000s). Ablation was not 
reflected in an acute change in OT or LT at 4 h after ablation 
compared to baseline, with the exception of AF patients, in 
whom heparin was administered after the baseline sample 
and where 4 h later, OT was prolonged, likely an effect of 
heparin, rather than the ablation.
Discussion
In this small exploratory study, successful treatment and 
restoration of SR in patients with AF using RFCA, is asso-
ciated with improved global thrombotic status as evidenced 
by enhanced fibrinolysis. This improvement was not seen in 
patients who had restoration of SR using DCCV. Our study 
is hypothesis generating and suggests that altering the sub-
strate of AF, through RFCA, not only improves the likeli-
hood of maintaining SR, but may favourably alter throm-
botic status.
A reduction of thrombotic risk would be expected with 
return of SR, in light of the restoration of effective mechani-
cal atrial contraction and reduction in stasis. Prior studies 
have raised the possibility that AF ablation may reduce 
thrombotic risk [12, 13]. A registry comparing 4212 patients 
undergoing AF ablation to 16,848 matched controls with AF 
but without ablation, showed that AF patients treated with 
ablation had much lower risk of death, stroke, and demen-
tia over 3-year follow-up, compared to AF patients without 
ablation [5, 8]. Furthermore, patients with AF ablation had 
similar long-term risk of stroke as patients without AF. This 
study however was not blinded or randomized, and the abla-
tion arm had much more vigorous management than the con-
trol arm. A retrospective analysis of 24,244 patients with AF 
undergoing DCCV or RFA, showed that long term, ablation 
is associated with a lower rate of death, stroke or transient 
ischaemic attack than DCCV [12]. Two ongoing studies, 
the catheter ablation versus anti-arrhythmic drug therapy 
for atrial fibrillation trial (CABANA) trial (clinicaltrials.gov 
identifier NCT00911508), a prospective, randomized trial 
comparing RFCA with optimal medical therapy and EAST 
(early treatment of atrial fibrillation for stroke prevention 
trial, clinicaltrials.gov identifier NCT01288352) comparing 
“early” RFCA and antiarrhythmic medications vs. current 
Table 3  (continued)
Values are mean ± standard deviation or n (%). Left ventricular ejection fraction was calculated by Simpson’s method
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CRP C-reactive protein, eGFR estimated glo-
merular filtration rate, INR international normalized ratio, LA left atrium, TIA transient ischaemic attack
Normal values: haemoglobin 130–180 g/L in men and 115–165 g/L in women; haematocrit 40–52% in men and 36–47% in women; platelet 
count 150–400 × 109/L; INR range 2.0–3.0; creatinine 60–110 μmol/L in men and 45–90 μmol/L in women; eGFR: above 90 mL/min/1.73 m2; 
total cholesterol < 5.2 mmol/L; CRP 0–10 mg/L; fibrinogen 2–5 g/L
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Table 4  Baseline clinical characteristics of radiofrequency catheter ablation (RFCA) cohort with respect to rhythm at follow-up
Patient characteristic RFCA cohort (n = 40) AF at follow-up n = 10 SR at follow-up n = 30 p value
Age, years 64 ± 13 67 ± 13 63.8 ± 14 0.418
Male 28 (70) 7 (70) 21 (70) 1.000
BMI 28.5 ± 5 31.6 ± 3.4 27.6 ± 5 0.064
Paroxysmal AF 10 (25) 3 (30) 7 (23) 0.766
Persistent AF 9 (23) 3 (30) 6 (20) 0.416
Long-standing persistent AF 21 (53) 4 (40) 17 (57) 0.444
Medical history
 Duration of AF > 1 year 29 (72.5) 7 (70) 22 (73) 1.000
 Previous ablations 13 (32.5) 5 (50) 8 (26.7) 0.479
 Hypertension 11 (27.5) 4 (40) 7 (23) 0.467
 Diabetes mellitus 5 (12.5) 0 5 (16.7) 0.571
 Hyperlipidemia 17 (42) 5 (50) 12 (40) 0.751
 Metabolic syndrome 10 (25) 4 (40) 6 (18) 0.014
 Coronary artery disease 8 (20) 2 (20) 6 (20) 1.000
 Prior stroke/TIA 4 (10) 0 4 (13.3) 0.559
 Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) 5 (12.5) 2 (20) 3 (10) 0.598
Echocardiographic characteristics
 Ejection fraction >55% 30 (75) 8 (80) 22 (73.3) 1.000
 Ejection fraction 45–54% 7 (17.5) 1 (10) 5 (16.7) 1.000
 Ejection fraction <44% 3 (7.5) 1 (10) 3 (10) 1.000
 No atrial dilatation 6 (15) 0 9 (30) 0.173
 Mild atrial dilatation (LA diameter 4.1–4.6 cm) 25 (62.5) 7 (70) 18 (60) 0.781
 Moderate atrial dilatation (LA diameter 4.7–5.2 cm) 5 (12.5) 2 (20) 0 0.077
 Severe atrial dilatation (LA diameter >5.3 cm) 4 (10) 1 (10) 3 (10) 1.000
Risk scores
 CHA2DS2-VASc 1.9 ± 1.7 2.2 ± 1.6 1.83 ± 1.8 0.571
 HASBLED 1.2 ± 0.7 1.1 ± 0.6 1.2 ± 0.7 0.691
Medications
 Warfarin 36 (90) 9 (90) 27 (90) 1.000
 Dabigatran 4 (10) 1 (10) 3 (10) 1.000
 Beta-blocker 21 (53) 2 (20) 19 (63) 0.189
 Calcium antagonist 6 (15) 4 (40) 2 (7) 0.060
 Digoxin 1 (3) 1 (10) 0 0.268
 Statin 17 (43) 6 (60) 11 (37) 0.523
 ACE inhibitor 6 (15) 3 (30) 3 (10) 1.000
 ARB 6 (15) 1 (10) 5 (17) 1.000
Laboratory characteristics
 Haemoglobin (g/L) 139 ± 17 144 ± 16 137 ± 15 0.217
 Haematocrit (%) 0.41 ± 4 0.42 ± 6 0.41 ± 4 0.326
 Platelet count (×109/L) 212 ± 58 227 ± 52 207 ± 59 0.244
 INR (warfarin patients) 2.3 ± 0.4 2.3 ± 0.4 2.3 ± 0.4 0.967
 Creatinine (μmol/L) 95 ± 84 93 ± 28 96 ± 10 0.137
 eGFR (mL/min/1.73 m2) 96.6 ± 28 85 ± 21 100.8 ± 30 0.35
Total cholesterol (mmol/L) 5.0 ± 1.7 4.5 ± 0.9 5.2 ± 1.9 0.523
 CRP (mg/L) 3.52 ± 4.18 3.3 ± 3.97 3.6 ± 4.31 0.847
 Fibrinogen (g/L) 4.06 ± 1.64 4.35 ± 1.32 3.96 ± 1.74 0.53
Procedure characteristics
 Procedure duration (min) 163 ± 76 247 ± 64 140 ± 62 0.001
 Ablation time (ms) 1856 ± 1408 3358 ± 1451 1446 ± 1108 0.002
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standard practice, will help define the role of ablation in 
reducing adverse clinical outcomes.
The DCCV cohort was sampled at 6 weeks and the RFCA 
cohort at 3 months. 3 months is the conventional period 
to assess RFCA outcome; however, we arranged DCCV 
follow-up at 6 weeks because of concern that beyond this, 
few patients would still be in SR. Thus, sampling times are 
not directly comparable in the two groups and the lack of 
Table 4  (continued)
Patient characteristic RFCA cohort (n = 40) AF at follow-up n = 10 SR at follow-up n = 30 p value
 Number of energy application 33 ± 24 56 ± 32 26 ± 17 0.005
Values are mean ± standard deviation or n (%). Left ventricular ejection fraction was calculated by Simpson’s method
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CRP C-reactive protein, eGFR estimated glo-
merular filtration rate, INR international normalized ratio, LA left atrium, TIA transient ischaemic attack
Normal values: haemoglobin 130–180 g/L in men and 115–165 g/L in women; haematocrit 40–52% in men and 36–47% in women; platelet 
count 150–400 × 109/L; INR range 2.0–3.0; creatinine 60–110 μmol/L in men and 45–90 μmol/L in women; eGFR: above 90 mL/min/1.73 m2; 
total cholesterol <5.2 mmol/L; CRP 0–10 mg/L; fibrinogen 2–5 g/L
Fig. 1  Distribution of occlusion time (OT) before (a) and after radiofrequency catheter ablation (RFCA) (b); and distribution of lysis time (LT) 
before (c) and after RFCA (d). Y-axis shows number of observations (subjects)
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improvement in LT following DCCV could be attributed 
to “stunning”, since it may take many weeks of restoration 
of mechanical contractility, not just electrical restoration 
of SR, to observe changes in thrombotic status. One could 
also postulate that the RFCA group may have more com-
plete freedom from paroxysmal atrial arrhythmias. The role 
of inflammation in the genesis and perpetuation of AF is 
increasingly recognized, with increasing AF burden asso-
ciated with increasing CRP [3, 14]. High-sensitivity CRP 
decreases after successful RFCA for long-standing persis-
tent AF, suggesting that AF itself may cause an inflamma-
tory response [14, 15]. This may explain why RFCA but 
not DCCV improved thrombotic profile, although conflicts 
with the lack of change in CRP following successful RFCA 
in our cohort.
Our study showing impaired endogenous fibrinolysis 
in AF that is improved by restoration of SR, is supported 
by data on circulating D-dimer levels. The hypercoagula-
ble state of AF is mirrored by increased levels of circulat-
ing D-dimer, a product of cross-linked fibrin degradation, 
reflecting activation of coagulation, fibrinolysis, or both. 
D-dimer levels are raised in AF and may identify those at 
high thromboembolic risk [3]. In small studies, both cardio-
version and RFCA caused an early rise in D-dimer within 
1–3 days, but the late effects of RFCA are less well docu-
mented. Lim showed that neither fibrinogen nor D-dimer 
levels fell 30 days after successful AF ablation, despite 
maintenance of SR, although a rise in fibrinogen level was 
associated with AF recurrence [16]. After successful AF 
ablation, some studies show CRP levels decrease signifi-
cantly [15] whilst others show no change.
The lack of change in platelet reactivity (OT) in response 
to RFCA, conflicts with an earlier study where mainte-
nance of SR 6 months after RFCA, was associated with 
reduced platelet activation and improvement in endothelial 
function [17]. However, whilst some studies have shown 
enhanced platelet activation in AF, others have not, or have 
documented only a local, and not systemic, phenomenon 
[2]. The role of platelet activation in AF therefore remains 
contentious.
Thrombotic status was similar in the left atrium and sys-
temic circulation, and is at odds with some earlier work, 
showing that platelet reactivity was increased in the left 
atrium compared to the peripheral circulation [18, 19]. How-
ever, impaired endogenous thrombolysis in the systemic cir-
culation is supported by a large volume of published data on 
the importance of circulating D-dimer levels in AF.
Limitations of our study include the fact that the DCCV 
cohort was assessed at 6 weeks and the RFCA cohort at 3 
months. Thus, any differences in thrombotic status between 
those who maintained SR after DCCV and after RFCA, may 
simply be due to timing, perhaps due to incomplete restora-
tion of left atrial mechanical contractility. We chose to sam-
ple patients post-RFA at 3 months because this is conven-
tionally regarded as the end of the “blanking period”. During 
the first 3 months after AF ablation, the so-called “blanking 
period”, a substantial proportion of patients experience early 
recurrences of atrial tachyarrhythmias [20, 21]. Such early 
recurrences are thought to be due to transient local inflam-
matory states unassociated with the risk of later AF recur-
rence, and thus do not necessarily represent treatment failure 
[20]. It has, therefore, become common practice to consider 
a periprocedural blanking period, during which recurrences 
are considered nonspecific and do not prompt reinterven-
tion. The Heart Rhythm Society/European Heart Rhythm 
Association/European Cardiac Arrhythmia Society expert 
consensus recommends using 3 months as the conventional 
post-procedural blanking period, as recurrence within the 
first 3 months after ablation is not significantly associated 
with procedural success or failure as up to 65% of patients 
with AF recurrence in the first few months post-ablation will 
not have any further arrhythmias during long-term follow up 
[21]. However, the problem is that post-cardioversion, many 
Fig. 2  Occlusion time (OT) and Lysis time (LT) before and after 
AF ablation, with respect to rhythm at follow-up. Sinus rhythm (SR) 
*p < 0.001
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patients revert to AF by 3 months, so we had to bring for-
ward the sampling point to 6 weeks post-DCCV to capture 
as many patients post-DCCV in sinus rhythm, as possible. 
Our DCCV and cardioversion cohorts were generally well 
matched but there were some differences, such as NOAC 
use. Another possible confounder is the difference in anti-
coagulant treatment type between the DCCV and the RFA 
groups. However, our study was done at a time when AF 
ablation was not routinely performed on NOACs and thus 
the sample population reflected clinical practice. However, 
whilst such differences in OAC may affect between group 
comparisons (between DCCV and RFA), it should not affect 
within-group comparisons (namely thrombotic status before 
and after DCCV, or before and after RFA) since patients 
acted as self-controls and continued on the same OAC treat-
ment throughout. Furthermore, we recently compared the 
Fig. 3  Upper panel change 
in lysis time before (a) and 
after (b) RFCA in individual 
patients, according to rhythm at 
follow-up. Lower panel change 
in lysis time before (a) and after 
(b) cardioversion in individual 
patients, according to rhythm at 
follow-up. Sinus rhythm (SR). 
*p < 0.001
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relative effects of different non-vitamin K antagonist oral 
anticoagulants (rivaroxaban, dabigatran and apixaban) and 
warfarin, on global thrombotic status in patients with AF. 
We showed that NOACs and warfarin had a similar favour-
able effect on reducing platelet reactivity (evidenced by sim-
ilar prolongation of OT with all agents). All NOACs exhib-
ited a trend toward enhancing endogenous thrombolytic 
status (as evidenced by reduced LT), this was significant 
only for apixaban [22]. Therefore, although there are differ-
ences in the type of OAC used between the two cohorts, the 
impact of this on the results of thrombosis tests is likely to 
be non-significant.
Arrhythmia relapse reporting was based on symptoms 
and 24-h Holter monitor and/or follow-up ECG. It is thus 
possible that some patients experienced paroxysms of AF 
during follow-up but were misclassified as arrhythmia-free. 
Our patients were a mixed cohort of paroxysmal and persis-
tent AF. Patients with paroxysmal AF may have intermediate 
levels of fibrin D-dimer compared to those with chronic AF 
or in SR which likely relates to fibrinolytic potential and thus 
the heterogeneous nature of our cohort may thus have been 
a potential confounder. However, against this is the finding 
that whilst the ratio of patients with paroxysmal AF was dif-
ferent between the DCCV and the RFA cohorts, OT and LT 
at baseline did not differ between the DCCV and RFA groups 
(Table 2). Furthermore, there was no difference in baseline 
OT or baseline LT between patients with different types of 
AF (paroxysmal, persistent, long-standing persistent). The 
GTT assesses platelet response to high shear, which does 
not replicate the low-flow state in the left atrium of patients 
with AF. However, unlike most low-flow states such as deep 
venous thrombosis where erythrocyte-rich thrombi prevail, 
in AF platelets contribute significantly to thrombus forma-
tion and the endothelial dysfunction which exists, suggests 
that an in vitro model like the GTT, where platelets and von 
Willebrand factor are key players and where endogenous 
fibrinolysis is assessed, may provide a useful assessment of 
this milieu. Furthermore, even if formed at low-flow states 
in the left atrium, such thrombi are subject to arterial flow, 
and our data and that of others suggest a systemic circula-
tory prothrombotic state and not just a localized left atrial 
phenomenon. The importance of endogenous fibrinolysis 
as a natural defence mechanism determining the outcome 
of thrombus formation is well recognized [23]. There are 
many physiological limitations to using single biomarkers 
to assess endogenous fibrinolysis, and emerging novel global 
assays of fibrinolysis such as used here have the potential 
to give a better overall assessment of thrombotic risk [23].
Conclusion
Successful restoration and maintenance of SR follow-
ing RFCA of AF is associated with improved global 
thrombotic status as evidenced by enhanced endogenous 
fibrinolysis. Our pilot data indicate the need for future 
large studies to investigate whether maintenance of SR 
with RFCA can reduce thrombotic risk in patients with 
AF.
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Fig. 4  Occlusion time (OT) before and after cardioversion, grouped 
with respect to rhythm at follow-up. Lysis time (LT) before and 
after cardioversion, grouped with respect to rhythm at follow-up. 
*p = 0.005. Sinus rhythm (SR)
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